Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 4, 2011, Pages 935-944

  Hwang, I G ^a   Jang, J S ^a   Do, J H ^a   Kang, J H ^b   Lee, G W ^b   Oh, S Y ^c   Kwon, H C ^c   Jun, H J ^d   Lim, H Y ^e   Lee, S ^f   Chi, K C ^a   Lee, S J ^a  

^a Chung Ang University College of Medicine   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

^c Dong A University College of Medicine   (South Korea)

^d Kwandong University College of Medicine   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f Kangwon National University College of Medicine   (South Korea)

Author keywords

Advanced biliary tract adenocarcinoma; Cisplatin; ERCC1; Oxaliplatin

Indexed keywords

CAPECITABINE; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED BILE DUCT ADENOCARCINOMA; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT ADENOCARCINOMA; BILE DUCT CARCINOMA; BILIARY TRACT ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CONTINUOUS INFUSION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN OVEREXPRESSION; SOUTH KOREA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CISPLATIN; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; REPUBLIC OF KOREA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80054768584     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1558-3     Document Type: Article

References (24)

1. S Al-Haddad Z Zhang E Leygue L Snell A Huang Y Niu T Hiller-Hitchcock K Hole LC Murphy PH Watson 1999 Psoriasin (S100A7) expression and invasive breast cancer Am J Pathol 155 2057 2066 10595935 10.1016/S0002-9440(10)65524-1 1:CAS:528:DC%2BD3cXit1Kguw%3D%3D
2. NR Bhagwat VY Roginskaya MB Acquafondata R Dhir RD Wood LJ Niedernhofer 2009 Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue Cancer Res 69 6831 6838 19723666 10.1158/0008-5472.CAN-09-1237 1:CAS:528: DC%2BD1MXhtVOmt7fL
3. MS Braun SD Richman P Quirke C Daly JW Adlard F Elliott JH Barrett P Selby AM Meade RJ Stephens MK Parmar MT Seymour 2008 Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial J Clin Oncol 26 2690 2698 18509181 10.1200/JCO.2007.15.5580 1:CAS:528: DC%2BD1cXnvVOhsb4%3D
4. M Dabholkar J Vionnet F Bostick-Bruton JJ Yu E Reed 1994 Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy J Clin Invest 94 703 708 8040325 10.1172/JCI117388 1:CAS:528:DyaK2cXlsVymsrg%3D (Pubitemid 24251002)
5. F Eckel RM Schmid 2007 Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials Br J Cancer 96 896 902 17325704 10.1038/sj.bjc.6603648 1:CAS:528:DC%2BD2sXjt1SrsLw%3D (Pubitemid 46452283)
6. D Fink S Nebel S Aebi H Zheng B Cenni A Nehme RD Christen SB Howell 1996 The role of DNA mismatch repair in platinum drug resistance Cancer Res 56 4881 4886 8895738 1:CAS:528:DyaK28XmsFygsbg%3D (Pubitemid 26374423)
7. L Gossage S Madhusudan 2007 Current status of excision repair cross complementing-group 1 (ERCC1) in cancer Cancer Treat Rev 33 565 577 17707593 10.1016/j.ctrv.2007.07.001 1:CAS:528:DC%2BD2sXhtVWmtLzJ (Pubitemid 47355341)
8. A Handra-Luca H Bilal JC Bertrand P Fouret 2003 Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation Am J Pathol 163 957 967 12937136 10.1016/S0002-9440(10)63455- 4 1:CAS:528:DC%2BD3sXnsVCju70%3D (Pubitemid 37040131)
9. S Hector W Bolanowska-Higdon J Zdanowicz S Hitt L Pendyala 2001 In vitro studies on the mechanisms of oxaliplatin resistance Cancer Chemother Pharmacol 48 398 406 11761458 10.1007/s002800100363 1:CAS:528:DC%2BD3MXnvFOlsLY%3D (Pubitemid 33027997)
10. AF Hezel AX Zhu 2008 Systemic therapy for biliary tract cancers Oncologist 13 415 423 18448556 10.1634/theoncologist.2007-0252 1:CAS:528:DC%2BD1cXmslKksbo%3D (Pubitemid 351679921)
11. HC Kwon MS Roh SY Oh SH Kim MC Kim JS Kim HJ Kim 2007 Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer Ann Oncol 18 504 509 17322540 10.1093/annonc/mdl430 (Pubitemid 46359630)
12. RV Lord J Brabender D Gandara V Alberola C Camps M Domine F Cardenal JM Sanchez PH Gumerlock M Taron JJ Sanchez KD Danenberg PV Danenberg R Rosell 2002 Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clin Cancer Res 8 2286 2291 12114432 1:CAS:528:DC%2BD38XmtVWhsLw%3D (Pubitemid 34753602)
13. LP Martin TC Hamilton RJ Schilder 2008 Platinum resistance: the role of DNA repair pathways Clin Cancer Res 14 1291 1295 18316546 10.1158/1078-0432.CCR- 07-2238 1:CAS:528:DC%2BD1cXislSku7c%3D (Pubitemid 351413906)
14. R Metzger CG Leichman KD Danenberg PV Danenberg HJ Lenz K Hayashi S Groshen D Salonga H Cohen L Laine P Crookes H Silberman J Baranda B Konda L Leichman 1998 ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy J Clin Oncol 16 309 316 9440758 1:CAS:528:DyaK1cXmsFeruw%3D%3D (Pubitemid 28041614)
15. LJ Niedernhofer N Bhagwat RD Wood 2007 ERCC1 and non-small-cell lung cancer N Engl J Med 356 2538 2540 17568038 10.1056/NEJMc070742 1:CAS:528:DC%2BD2sXms1Siurg%3D author reply 2540-1
16. KA Olaussen A Dunant P Fouret E Brambilla F Andre V Haddad E Taranchon M Filipits R Pirker HH Popper R Stahel L Sabatier JP Pignon T Tursz T Le Chevalier JC Soria 2006 DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 983 991 16957145 10.1056/NEJMoa060570 1:CAS:528:DC%2BD28XpsFKmtLw%3D (Pubitemid 44343542)
17. KA Olaussen JC Soria 2010 Validation of ERCC1-XPF immunodetection-letter Cancer Res 70 3851 3852 20406965 10.1158/0008-5472.CAN-09-4352 1:CAS:528:DC%2BC3cXltlensbo%3D author reply 3852
18. JT Reardon A Vaisman SG Chaney A Sancar 1999 Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts Cancer Res 59 3968 3971 10463593 1:CAS:528:DyaK1MXlsVOltLo%3D (Pubitemid 29393563)
19. C Reynolds C Obasaju MJ Schell X Li Z Zheng D Boulware JR Caton LC Demarco MA O'Rourke G Shaw Wright KA Boehm L Asmar J Bromund G Peng MJ Monberg G Bepler 2009 Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer J Clin Oncol 27 5808 5815 19884554 10.1200/JCO.2009.21.9766 1:CAS:528:DC%2BC3cXhtVWitrw%3D
20. Y Shirota J Stoehlmacher J Brabender YP Xiong H Uetake KD Danenberg S Groshen DD Tsao-Wei PV Danenberg HJ Lenz 2001 ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy J Clin Oncol 19 4298 4304 11731512 1:CAS:528:DC%2BD3MXptlGjtLk%3D (Pubitemid 33096777)
21. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
22. K Tozawa T Oshima T Kobayashi N Yamamoto C Hayashi T Matsumoto H Miwa 2008 Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer Anticancer Res 28 2087 2092 18751380 1:CAS:528:DC%2BD1cXhtVaku77M
23. J Valle H Wasan DH Palmer D Cunningham A Anthoney A Maraveyas S Madhusudan T Iveson S Hughes SP Pereira M Roughton J Bridgewater 2010 Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 1273 1281 20375404 10.1056/NEJMoa0908721 1:CAS:528:DC%2BC3cXksVyiuro%3D
24. J Wei Z Zou X Qian Y Ding L Xie JJ Sanchez Y Zhao J Feng Y Ling Y Liu L Yu R Rosell B Liu 2008 ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen Br J Cancer 98 1398 1402 18362936 10.1038/sj.bjc.6604317 1:CAS:528:DC%2BD1cXks12gu7w%3D (Pubitemid 351543582)